Literature DB >> 29666981

An Early Life Mucosal Insult Temporarily Decreases Acute Oxazolone-Induced Inflammation in Mice.

Katja M Bendtsen1, Peter Tougaard1, Axel K Hansen2.   

Abstract

Inflammatory priming of immune cells in early life may optimize the response to a subsequent inflammatory challenge later in life. To prime the immune cells in the gut in vivo through a short inflammatory insult, we administered a low dose of dextran sulfate sodium (DSS) to 5-weeks-old BALB/c mice in the drinking water. We hypothesized that DSS-primed mice would show decreased inflammation and difference in immunological profiling, when subjected to presensitizing and oxazolone-induced colitis by rectal instillation at 9 weeks compared to non-DSS-primed control mice. In fact, this low-dose DSS priming apparently decreased the acute inflammation, as colitis scores along with IFNγ, IL-1ß, and IL-4 were significantly decreased with the same tendency for IL-5, TNFα, and IL-2 on day 3 post-induction compared to control mice. On day 7, both DSS-primed and control mice had significantly higher numbers of FoxP3+CD8+ regulatory T cells, while they did not differ in any inflammation parameters. No significant differences were found for intraepithelial lymphocytes or mesenteric lymphocytes at any time point after colitis induction. In conclusion, the priming did decrease local acute tissue inflammation of the colon in this commonly applied mouse model of T helper cell type 2-dominated model of inflammatory bowel disease.

Entities:  

Keywords:  acute inflammation; colitis; dextran sulfate sodium; oxazolone; priming

Mesh:

Substances:

Year:  2018        PMID: 29666981     DOI: 10.1007/s10753-018-0790-y

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  32 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

2.  Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria.

Authors:  Chin Wen Png; Sara K Lindén; Kristen S Gilshenan; Erwin G Zoetendal; Chris S McSweeney; Lindsay I Sly; Michael A McGuckin; Timothy H J Florin
Journal:  Am J Gastroenterol       Date:  2010-07-20       Impact factor: 10.864

3.  Epithelial IL-18 Equilibrium Controls Barrier Function in Colitis.

Authors:  Roni Nowarski; Ruaidhrí Jackson; Nicola Gagliani; Marcel R de Zoete; Noah W Palm; Will Bailis; Jun Siong Low; Christian C D Harman; Morven Graham; Eran Elinav; Richard A Flavell
Journal:  Cell       Date:  2015-12-03       Impact factor: 41.582

4.  Low relative abundances of the mucolytic bacterium Akkermansia muciniphila and Bifidobacterium spp. in feces of children with autism.

Authors:  Lv Wang; Claus T Christophersen; Michael J Sorich; Jacobus P Gerber; Manya T Angley; Michael A Conlon
Journal:  Appl Environ Microbiol       Date:  2011-07-22       Impact factor: 4.792

5.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

6.  Biomechanical changes in oxazolone-induced colitis in BALB/C mice.

Authors:  Jian Yang; Jingbo Zhao; Toshiya Nakaguchi; Hans Gregersen
Journal:  J Biomech       Date:  2009-03-05       Impact factor: 2.712

7.  Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice.

Authors:  L A Dieleman; B U Ridwan; G S Tennyson; K W Beagley; R P Bucy; C O Elson
Journal:  Gastroenterology       Date:  1994-12       Impact factor: 22.682

8.  Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes.

Authors:  Christopher T Brown; Austin G Davis-Richardson; Adriana Giongo; Kelsey A Gano; David B Crabb; Nabanita Mukherjee; George Casella; Jennifer C Drew; Jorma Ilonen; Mikael Knip; Heikki Hyöty; Riitta Veijola; Tuula Simell; Olli Simell; Josef Neu; Clive H Wasserfall; Desmond Schatz; Mark A Atkinson; Eric W Triplett
Journal:  PLoS One       Date:  2011-10-17       Impact factor: 3.240

9.  Human and Mouse CD8(+)CD25(+)FOXP3(+) Regulatory T Cells at Steady State and during Interleukin-2 Therapy.

Authors:  Guillaume Churlaud; Fabien Pitoiset; Fadi Jebbawi; Roberta Lorenzon; Bertrand Bellier; Michelle Rosenzwajg; David Klatzmann
Journal:  Front Immunol       Date:  2015-04-15       Impact factor: 7.561

10.  Gut microbiota and lipopolysaccharide content of the diet influence development of regulatory T cells: studies in germ-free mice.

Authors:  Tomas Hrncir; Renata Stepankova; Hana Kozakova; Tomas Hudcovic; Helena Tlaskalova-Hogenova
Journal:  BMC Immunol       Date:  2008-11-06       Impact factor: 3.615

View more
  4 in total

1.  Effect of gluten-free diet and antibiotics on murine gut microbiota and immune response to tetanus vaccination.

Authors:  Pernille Kihl; Lukasz Krych; Ling Deng; Lars H Hansen; Karsten Buschard; Søren Skov; Dennis S Nielsen; Axel Kornerup Hansen
Journal:  PLoS One       Date:  2022-04-13       Impact factor: 3.240

2.  A Humanized Diet Profile May Facilitate Colonization and Immune Stimulation in Human Microbiota-Colonized Mice.

Authors:  Isabel Moreno-Indias; Randi Lundberg; Lukasz Krych; Stine Broeng Metzdorff; Witold Kot; Dorte Bratbo Sørensen; Dennis Sandris Nielsen; Camilla Hartmann Friis Hansen; Axel K Hansen
Journal:  Front Microbiol       Date:  2020-06-19       Impact factor: 5.640

3.  Long-term inhibition of dipeptidyl-peptidase 4 reduces islet infiltration and downregulates IL-1β and IL-12 in NOD mice.

Authors:  Xinran He; Wangen Li; Yunliang Xie; Yunjuan Zhao
Journal:  Int Immunopharmacol       Date:  2020-09-23       Impact factor: 4.932

4.  An Oligosaccharide Rich Diet Increases Akkermansia spp. Bacteria in the Equine Microbiota.

Authors:  Frederikke Christine Lindenberg; Ditte Olsen Lützhøft; Lukasz Krych; James Fielden; Witold Kot; Hanne Frøkiær; Gaby van Galen; Dennis Sandris Nielsen; Axel Kornerup Hansen
Journal:  Front Microbiol       Date:  2021-05-21       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.